PTLD develops in approximately 1 in 5 recipients of EBV-positive donor kidneys, a much higher rate than previously thought. Recipients of kidney transplants infected with Epstein-Barr virus (EBV) have ...
The US Food and Drug Administration (FDA) has accepted the biologics licence application (BLA) and granted priority review for Pierre Fabre Pharmaceuticals’ Tabelecleucel (Tab-cel) to treat ...
Monitoring Epstein-Barr virus (EBV) levels after liver transplantation to avoid over-immunosuppression showed a signal for less post-transplant lymphoproliferative disease (PTLD) over the long term in ...
In the article that accompanies this editorial, Icheva et al 11 used donor-derived Epstein-Barr nuclear antigen 1 (EBNA1) –specific T cells to treat post-HSCT PTLD. CTLs were generated with ...
Monitoring and Risk-Based Therapeutic Strategy Eliminates Posttransplant Lymphoproliferative Disease
July 11, 2008 (Paris, France) — The retrospective evaluation of a preventative and preemptive intervention for pediatric recipients of liver transplants has shown that a combination of prophylactic ...
According to the CRL, the product could not be approved based on inspection findings at a third party manufacturing facility. The Food and Drug Administration (FDA) has issued a Complete Response ...
Transplants can trigger EBV reactivation, leading to EBV-positive PTLD, with poor survival if rituximab fails. Tabelecleucel (tab-cel) shows promise in treating refractory EBV+ PTLD, with significant ...
Recipients of solid-organ transplants receive immunosuppressive therapy to prevent allograft rejection. Immunosuppressive therapy can be divided into induction therapy, administered in the ...
There is no universally accepted definition of PTLD. The term generally refers to a spectrum of B-cell hyperproliferative states, and includes benign conditions such as infectious mononucleosis-like ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results